MimiVax has filed a notice of an exempt offering of securities to raise $5,781,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, MimiVax is raising up to $5,781,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Ciesielski played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About MimiVax
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through: – Phase 1 clinical trials in multiple myeloma combination with REVLIMID (lenalidomide) – Phase 1 in Neuro-Endocrine Tumors (NET) – Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG .
To learn more about MimiVax, visit http://www.mimivax.com/
MimiVax Linkedin Page: https://www.linkedin.com/company/mimivax/
Contact:
Michael Ciesielski, Chief Executive Officer
716-853-5100
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.